IGKV2D-28: A Potential Drug Target and Biomarker (G28883)

Target Name: IGKV2D-28

NCBI ID: G28883

Other Name(s): IGKV2D28 | Immunoglobulin kappa variable 2D-28 | immunoglobulin kappa variable 2D-28 | A3

IGKV2D-28: A Potential Drug Target and Biomarker

The IGKV2D28 gene has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGKV2D-28 is a non-coding RNA molecule that is located on chromosome 12q34 and has been shown to play a role in various cellular processes, including DNA replication, gene expression, and cell signaling.

Disease-Related Functions of IGKV2D-28

IGKV2D-28 has been shown to be involved in several diseases and disorders, including:

1. Cancer: IGKV2D-28 has been associated with the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. Studies have shown that IGKV2D-28 can promote the growth and survival of cancer cells and can also inhibit the effectiveness of cancer treatments.
2. Neurodegenerative Diseases: IGKV2D-28 has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that IGKV2D-28 can cause misfolding of the protein tau and contribute to the development of neurodegeneration.
3. Autoimmune Disorders: IGKV2D-28 has been associated with the development and maintenance of several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that IGKV2D-28 can cause the production of antibodies that target self-antigens and contribute to the development of autoimmune disorders.

Potential Therapeutic Interventions

Several therapeutic interventions have been proposed to target IGKV2D-28 and treat associated diseases. These interventions include:

1. Drug Treatments: Several drugs have been developed to target IGKV2D-28 and treat associated diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These drugs can include small molecules, antibodies, and signaling agents that target IGKV2D-28.
2. Biomarkers: IGKV2D-28 can also serve as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Researchers can use IGKV2D-28 as a target for diagnostic tests, such as liquid biopsy, to diagnose these diseases at an early stage.

Conclusion

IGKV2D-28 is a non-coding RNA molecule that has been associated with several diseases and disorders. Its functions in cellular processes include DNA replication, gene expression, and cell signaling. Several therapeutic interventions have been proposed to target IGKV2D-28 and treat associated diseases. Further research is needed to understand the full role of IGKV2D-28 in disease and to develop effective therapies.

Protein Name: Immunoglobulin Kappa Variable 2D-28

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets